🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis

Recruitingn/aAges 18 Years - anyAllNanfang Hospital, Southern Medical University
NCT06307314 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year. At present, radiotherapy is an important measure to control the recurrence of head and neck tumors, but almost all patients with head and neck squamous cell carcinoma will have acute inflammatory reactions such as radiotherapy-induced oral mucositis (RIOM) after radiotherapy, which seriously affects the quality of life and radiotherapy efficacy of patients. Serum amyloid A1 (SAA1) is an acute phase protein associated with inflammation. Our previous basic research found that serum SAA1 expression levels can be used as biomarkers to assess the dose received by the receptor in the early stages of radiation damage. At the same time, we confirmed that the serum level of SAA1 in patients with nasopharyngeal carcinoma increased after rad

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Over 18 years of age. * Voluntarily sign informed consent. * The pathological diagnosis was nasopharyngeal carcinoma, head and neck tumor. * Need to be treated with radiotherapy. * ECOG PS Score: 0/1. Exclusion Criteria: * There are contraindications to radiotherapy. * Combined with other tumors. * Patients had any serious coexisting medical conditions that could pose an unacceptable risk or negatively affect trial adherence. For example, unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor disease status, uncontrolled diabetes (fasting blood glucose \> 1.5 × ULN), and mental illness. * At the investigator's discretion, those who was not considered to be suitable for participation in the study.
💊

What it tests

  • Not listed
📍

Where

5 sites
Nanfang hospital, Southern medical university
Guangzhou, China
Fujian Provinical Hospital
Fuzhou, China
Huizhou Central People's Hospital
Huizhou, China
Jieyang People's Hospital
Jieyang, China
Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou
Meizhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy